The associated targets of SGR in the treatment of myasthenia gravis have been shown to focus primarily on the PI3K-Akt signaling pathway, the TNF-α and IL-17 signaling pathways, and Th17 cell differentiation, which are conventional pathways for the pathogenesis and development of myasthenia gravis. The gene discussed is AKT1; the disease is myasthenia gravis.